We performed a prospective, randomized, double-blind, crossover study to compare the efficacy and safety of vasodilation with the calcium entry blocker nifedipine with that of isosorbide dinitrate (ISDN) seconds on nifedipine, and 372+92 and 384±100 seconds on nifedipine-ISDN combination therapy; p <0.05 versus baseline). These changes in exercise time, however, were not associated with a significant change in maximal oxygen uptake. We conclude that the administration of nifedipine alone or in combination with ISDN in patients with chronic heart failure due to left ventricular systolic dysfunction who demonstrate relative stability during ISDN therapy results in firuent clinical deterioration necessitating treatment. Worsening heart failure cannot be predicted by resting left ventricular ejection fraction or functional capacity as measured by maximal oxygen uptake. These findings demonstrate the potential hazard associated with the use of calcium entry blockers with nifedipine for vasodilation in patients with mild to moderate chronic heart failure due to left ventricular systolic dysfunction. (Circulation 1990;82:1954-1961 
This drug has a strong arterial dilatory effect resulting in a marked decrease in peripheral vascular resistance and augmentation of cardiac output'1 and has been suggested by several investigators as an effective treatment for patients with heart failure.12-'9 However, occasional reports of depression in cardiac performance"1 [20] [21] [22] attributed to the negative inotropic effect of nifedipine have raised concern regarding the usefulness and safety of this therapeutic approach.10"' These conflicting results and the lack of controlled, long-term clinical trials clearly indicate the need for additional studies to further define the potential role of nifedipine in the treatment of patients with chronic heart failure due to left ventricular systolic dysfunction.10,23-25 The present study was therefore designed to evaluate the safety and efficacy of chronic arterial dilation with nifedipine alone and in combination with venodilation with ISDN compared with ISDN alone in patients with mild to moderate heart failure due to left ventricular systolic dysfunction who are treated with digoxin and diuretics.
Methods

Patient Selection
The present study was designed to include male or female patients between 18 and 75 years old who had a well-documented history of congestive heart failure of at least 1 month's duration with symptoms consistent with New York Heart Association (NYHA) functional class II or 11126 and left ventricular ejection fraction of less than 40%. All patients had to be capable of performing treadmill exercise testing and of remaining clinically stable on a constant maintenance dose of digitalis and diuretics during an initial stabilization period of at least 2 weeks. Exercise testing had to be limited by symptoms of congestive heart failure such as dyspnea or exhaustion.
Criteria for exclusion from the study were being pregnant, being of childbearing potential, or currently nursing; history of acute myocardial infarction within the first month before study entry; primary valvular disease as a reason for symptoms; angina pectoris; cardiomyopathy other than dilated congestive cardiomyopathy; significant primary pulmonary, hepatic, renal, or hematological disease; and inability to give informed consent.
Study Protocol
The study consisted of the following four phases ( Figure 1 ).
Phase 1-Stabilization period. This phase consisted of a single-blinded, placebo, baseline period lasting for at least 2 weeks during which all patients continued to take digoxin and diuretics at their usual established dosage. All other vasodilators were discontinued, and each patient was instructed to take one nifedipine placebo capsule q.i.d. plus one ISDN placebo tablet q.i.d. Exercise treadmill test (ETT) was given to all patients at the end of the first and second weeks at 2 and 4 hours after dose administration with determination of maximal oxygen consumption (Vo2max). These two ETTs had to demonstrate a less-than-20% difference in exercise time at both 2 and 4 hours. When there was a more-than-20% difference between tests, the ETT was repeated within 3-6 days until two consecutive ETTs with exercise times of 20% or less were achieved.
After successful completion of phase 1, all patients were randomized to one of three possible doubleblinded study drug regimens: 1) active nifedipine plus ISDN placebo, 2) active ISDN plus nifedipine placebo, and 3) active nifedipine plus active ISDN. Randomization was conducted according to a Latin square design by the use of a computer-generated randomization code. Dosage of study medications was titrated on a patient-by-patient basis according to the safety titration procedure outlined below. Phases 2, 3, and 4-Efficacy periods. Phases [2] [3] [4] consisted of three identical double-blinded, study drug administration periods lasting for 8 weeks each. The study was designed for each patient to cross over to a different study drug treatment regimen every 8 weeks so that by the end of the study, all patients would have received all three treatment regimens in a random fashion. ETTs Fifty-one patients with a history of heart failure entered the stabilization period. Twenty-three patients were excluded before randomization for noncompliance (eight patients), NYHA functional class I as determined by symptoms25 and Vo2max of 20 ml/kg/min or more27 (six patients), worsening of heart failure (four patients), chronic obstructive pulmonary disease (two patients), angina-limiting ETT (two patients), and inability to walk on the treadmill (one patient). Twenty-eight patients were randomized and entered phase 2 of the study. Five randomized patients were excluded from the study due to noncompliance (two patients), psychiatric disorder (one patient), and loss to follow-up after the initiation of the study (two patients). Therefore, data analysis comprises the remaining 23 patients.
Treadmill Exercise Time
Two patients were discontinued from the study due to worsening of heart failure, and one patient died during phase 2; therefore, 20 of the 23 remaining patients completed at least phase 2 of the study and were included in the analysis of treadmill exercise time (Figure 2 severe worsening of CHF and cardiopulmonary arrest (one patient). Discussion The present study demonstrates an increased incidence of cardiovascular morbidity during 8 weeks of therapy with nifedipine in patients with heart failure who demonstrate relative stability during ISDN therapy. The use of nifedipine resulted in worsening CHF and hospitalization or intensive diuretic therapy in 38% of the patients. In 32% of the patients, dose reduction or premature discontinuation of therapy were necessary mainly due to worsening CHF, fatigue, or symptomatic hypotension. The clinical deterioration during nifedipine therapy seen in the present study was probably caused by previously demonstrated concomitant arterial dilatory and myocardial depressant effects of nifedipine in patients with CHF due to inhibition of intracellular calcium influx.' Although nifedipine-mediated reduction in cardiac muscle force development in patients with normal left ventricular systolic function is usually offset by the vasorelaxing effect of the drug and its consequent reflex augmentation of 13-adrenergic activity,15"16'28'29 this "protective" mechanism often fails in patients with chronic CHF in whom baroreceptor sensitivity is known to be markedly attenuated.30 Such a depression in baroreceptor responsiveness may explain the lack of change in heart rate in the present study and in sympathetic response to nifedipine in previous studies despite a significant decrease in systemic blood pressure.3' Although direct depression of myocardial contractility is the most likely mechanism of clinical deterioration during nifedipine therapy, a previously reported increase in plasma renin activity with nifedipine31"32 may lead to an increased angiotensin II level and thus to worsening of CHF due to its vasoconstrictive action as well as its stimulation of sodium and water retention.
The findings of clinical deterioration secondary to nifedipine therapy are in accordance with previous reports from our group and others demonstrating hemodynamic and clinical worsening after nifedipine administration in patients with CHF.1",2',33-36 Agostoni et a136 compared the effects of captopril with those of nifedipine in a double-blinded, placebocontrolled, crossover fashion. Although a significant improvement was reported by these investigators with captopril, nifedipine therapy resulted in increased body weight and worsening of symptoms in many of the patients. Similarly, a preliminary report by Packer et a121 described symptomatic deterioration in 29% of CHF patients after a single dose of nifedipine.
A previous report by our group on the spectrum of hemodynamic response to nifedipine"l described de- In contrast to ISDN, nifedipine resulted in a significant decrease in diastolic systemic blood pressure. Similar findings have been previously described with acute administration of the drug to similar patient populations.35 Although initial therapy with nitrates has also been reported to reduce blood pressure in patients with CHF, this response has been shown to be significantly attenuated with chronic therapy. 37 Despite a higher incidence of clinical deterioration with nifedipine and the combination therapy in comparison to ISDN alone, no difference was noted in change in exercise time and Vo2max during treatment with the three drug regimens studied. These findings may seem paradoxical and are probably explained by intensive use of additional diuretic agents for worsening heart failure in some patients38,39 during nifedipine therapy and by the exclusion of others who demonstrated clinical deterioration during therapy, thus biasing the data in favor of the drug. In addition, previous studies of vasodilator therapy for heart failure have shown that effective therapy exhibits a progressive improvement in exercise time that may take 12 weeks or longer to reach its maximum37,4041; thus, the study period may not have been long enough to separate the effect of ISDN from that of nifedipine. Total exercise time on all three drug regimens was significantly longer than the time recorded during prerandomization baseline evaluation. Because the study was designed to compare the effects of all three regimens with each other rather than with that of placebo, the analysis of changes in exercise performance within each group may not be valid, and it is therefore unclear whether this improvement can be attributed to the drugs. Similar improvement in exercise performance was reported during placebo therapy in patients with heart failure4243 and may be attributed to training effect, improvement of overall patient care, and increased motivation during the trial. Despite the increase in exercise time seen with all three treatments, no significant change was noted in Vo2max, demonstrating failure to increase capacity of oxygen transport to exercising muscles.27 A similar discrepancy between changes in exercise duration and Vo2max was reported by Wilson et a144 to be associated with increased levels of lactate, and these changes have been attributed to increased motivation to perform. Another potential explanation of our findings, however, may be a delay in the onset of anaerobic metabolism and lactate accumulation due to drug-mediated increased blood flow to exercising muscles at submaximal load, resulting in prolongation of total exercise duration without change in Vo2max. 45 Reports of the effects of calcium antagonists on exercise performance in patients with heart failure are limited. A previous study by Agostoni et a136 demonstrated no significant improvement in exercise time during 2 months of nifedipine therapy. Simi- larly, the use of felodipine, a new calcium antagonist vasodilator, also failed to improve exercise capacity in patients with CHF of moderate severity. 46 Although the present study population is larger than those of previously published trials evaluating long-term effect of calcium entry-blocking agents in patients with CHF, the total number of patients is limited. This limitation is partially corrected by the crossover design of the trial, which allows direct comparison of all three treatments in the same patients. Such an approach eliminates the influence of difference in patient characteristics seen in parallel group design.47 Inability to assess all three treatments in every patient due to death or premature crossover is an inherent weakness of the crossover design and may also limit the results of the present study. A comparison of all three drug regimens when given during the first study period, however, supports the overall results of the study, which demonstrate a higher incidence of CHF-worsening episodes on nifedipine alone and nifedipine-ISDN combination than on ISDN alone.
The conclusions drawn in the present study regarding drug effect on clinical status could have been strengthened if carry-over effects from one agent to the next could be excluded. Because treatments were given consecutively in a crossover fashion, there is no simple way to assess for carry-over effects. A paucity of CHFworsening episodes within the first week after crossovers, however, suggests a low likelihood of carry-over effects. In addition, the marked contrast in clinical status during the ISDN treatment period and the other two treatment periods using nifedipine should rule out residual effect of ISDN as a cause for clinical deterioration during subsequent treatment. Our findings are also supported by those from previous studies demonstrating either stability or symptomatic improvement with ISDN37,40 or hemodynamic as well as symptomatic deterioration with nifedipine.10t11 ISDN has been widely used for the treatment of chronic CHF and has been served in the present study as a reference treatment for the assessment of the safety and efficacy of arterial dilation with nifedipine. The selection of the 40-mg dose of ISDN given four times daily as a standard treatment in this study was based on reports indicating the long-term efficacy of this drug and dose.3,37,4048 During the time required to complete the present study, doubt had been raised regarding the real efficacy of nitrates in the treatment of CHF. 49 In addition, findings of resistance to the standard ISDN dose in many patients50 and demonstration of early tolerance development to frequent dosing intervals51,52 resulted in recommendations for the use of higher dosages given only twice or thrice daily.49,51 The present study demonstrated a favorable clinical course and side-effect profile during therapy with ISDN alone compared with nifedipine. However, with the lack of a concomitant placebo period, the absolute effect of ISDN cannot be determined. Our study, however, clearly demonstrates that the addition of 40 mg ISDN given four times daily does not prevent nifedipine-mediated clinical deterioration as indicated by a similar number of patients who had worsening of CHF episodes during therapy with this drug combination.
Summary
The present study compared in a prospective, randomized, and double-blinded fashion the effect of 8 weeks of vasodilator therapy with nifedipine. ISDN, and their combination in patients with mild to moderate chronic heart failure (NYHA functional classes II and III). The outcome of this trial indicates that despite similar effects of all three drug regimens on exercise performance, the use of nifedipine alone or in combination with ISDN is associated with a significantly higher incidence of clinical deterioration and worsening of CHF. Deterioration in clinical status was not predictable by pretreatment severity of CHF as manifested by ejection fraction or functional classification determined by Vo2max. These findings substantiate previous reports of hemodynamic deterioration with short-term nifedipine therapy and demonstrate the potential hazard associated with the use of this drug in patients without active myocardial ischemia who have chronic CHF due to left ventricular systolic dysfunction.
